Tecentriq (Atezolizumab) vs Trodelvy (sacituzumab govitecan-hziy)

Tecentriq (Atezolizumab) is an immune checkpoint inhibitor that works by blocking the protein PD-L1, which is known to suppress the immune response, thus allowing the immune system to better detect and fight cancer cells. Trodelvy (sacituzumab govitecan-hziy), on the other hand, is an antibody-drug conjugate that targets the Trop-2 receptor on cancer cells to deliver a potent chemotherapy drug directly to the tumor, minimizing effects on healthy cells. The choice between these two medications would depend on the specific type of cancer being treated, its expression of certain markers like PD-L1 or Trop-2, and the patient's overall health, with a healthcare provider's guidance being crucial to determine the most appropriate treatment option.

Difference between Tecentriq and Trodelvy

Metric	Tecentriq (Atezolizumab)	Trodelvy (sacituzumab govitecan-hziy)
Generic name	Atezolizumab	Sacituzumab govitecan-hziy
Indications	Urothelial carcinoma, non-small cell lung cancer, triple-negative breast cancer, small cell lung cancer	Metastatic triple-negative breast cancer, metastatic urothelial cancer
Mechanism of action	PD-L1 inhibitor	Antibody-drug conjugate targeting Trop-2
Brand names	Tecentriq	Trodelvy
Administrative route	Intravenous infusion	Intravenous infusion
Side effects	Fatigue, decreased appetite, nausea, urinary tract infections, fever, etc.	Neutropenia, diarrhea, nausea, fatigue, anemia, vomiting, etc.
Contraindications	Known hypersensitivity to atezolizumab or any of its excipients	Known hypersensitivity to sacituzumab govitecan-hziy or any of its excipients
Drug class	Monoclonal antibody, Immune checkpoint inhibitor	Antibody-drug conjugate
Manufacturer	Genentech (Roche)	Immunomedics, Inc. (a subsidiary of Gilead Sciences)

Efficacy

Efficacy of Tecentriq (Atezolizumab) in Breast Cancer

Tecentriq (Atezolizumab) is an immune checkpoint inhibitor that has shown efficacy in treating triple-negative breast cancer (TNBC), a particularly aggressive form of the disease. The drug works by targeting the PD-L1 protein, which can help cancer cells evade immune detection. In clinical trials, Tecentriq has been used in combination with chemotherapy and has demonstrated a significant improvement in progression-free survival in patients with advanced TNBC. Specifically, the IMpassion130 trial revealed that patients with PD-L1-positive tumors experienced a median progression-free survival of 7.5 months with Tecentriq plus nab-paclitaxel, compared to 5.0 months with placebo plus nab-paclitaxel.

Moreover, the overall survival was also improved in the PD-L1-positive population when treated with Tecentriq in combination with nab-paclitaxel. However, it is important to note that the benefits of Tecentriq in breast cancer are primarily observed in patients whose tumors express the PD-L1 protein. Therefore, PD-L1 testing is crucial before considering Tecentriq as a treatment option for breast cancer.

Efficacy of Trodelvy (sacituzumab govitecan-hziy) in Breast Cancer

Trodelvy (sacituzumab govitecan-hziy) is an antibody-drug conjugate designed to deliver a potent chemotherapy drug directly to cancer cells. It targets the Trop-2 receptor, which is commonly overexpressed in many epithelial cancers, including TNBC. Trodelvy has shown promising results in the treatment of metastatic TNBC. In a pivotal phase III trial (ASCENT), patients treated with Trodelvy demonstrated a significant improvement in progression-free survival compared to those who received standard chemotherapy. The median progression-free survival was 5.6 months for Trodelvy compared to 1.7 months for chemotherapy.

Furthermore, Trodelvy significantly extended overall survival in patients with metastatic TNBC. The median overall survival in the Trodelvy group was 12.1 months compared to 6.7 months in the chemotherapy group. The results of this trial have led to the approval of Trodelvy for patients with metastatic TNBC who have received at least two prior therapies for metastatic disease. Trodelvy represents an important advancement in the treatment of this challenging form of breast cancer, offering hope to patients who have limited treatment options.

Regulatory Agency Approvals

Tecentriq

European Medical Agency (EMA), European Union
Food and Drug Administration (FDA), USA
Health Canada
Pharmaceuticals and Medical Devices Agency (PMDA), Japan
Therapeutic Goods Administration (TGA), Australia
Medsafe (NZ)

Trodelvy

European Medical Agency (EMA), European Union
Food and Drug Administration (FDA), USA

Access Tecentriq or Trodelvy today

If Tecentriq or Trodelvy are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.

Buy Tecentriq

Buy Trodelvy

How it works

Make an enquiry

Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.

Breeze through the paperwork

We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.

Get a personalized quote

We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.

Receive your medicine

Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.

Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.

Let's talk

If you have any questions, call us or send us a message through WhatsApp or email: